Log In
BCIQ
Print this Print this
 

Anti-NGF antibody, fulranumab (AMG 403)

  Manage Alerts
Collapse Summary General Information
Company Amgen Inc.
DescriptionHumanized IgG2 mAb against nerve growth factor (NGF)
Molecular Target Nerve growth factor (NGF)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationPain
Indication DetailsTreat cancer pain; Treat chronic and neuropathic pain; Treat chronic low back pain; Treat chronic pain; Treat neuropathic pain; Treat osteoarthritis (OA) pain of the hip and knee
Regulatory Designation
PartnerJohnson & Johnson

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today